OUR MISSION
The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
OFFERING
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
- Proprietary consumer insights on attitudes, uses and behaviours
- Deep dives into the most transformative compounds and companies
- Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS AND INSIGHTS
PSYCH: What are the next steps
for investors?
PSYCH: What Lies Ahead?
The Future of Therapy
PSYCH: Psychedelics for
Substance Use
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS & INSIGHT
Professor David Nutt: The Therapeutic Use of Psychedelics
During The PSYCH Symposium in November 2020, Professor David Nutt, chairman of Awakn Life Sciences, founder of Drug Science and the director of neuropsychopharmacology at Imperial College London, delivered a virtual keynote speech on the impact of psychedelic medicines across history and culture before covering the complex and unbridled potential they hold in the treatmentContinue reading
Gwella and the Untapped Opportunity In Functional Mushrooms
A new company straddling both the functional health and psychedelic space with a consumer/retail first approach. Backed by a leading team of scientists, doctors, investors and experts across the wellness space, the company has full service creative, digital marketing, and e-commerce expertise, which is supported by a board with extensive knowledge of developing, marketing andContinue reading
St. Vincent and the Grenadines Launch Psychedelics Initiative
Exclusive: Saint Vincent and the Grenadines announces initiative to permit psychedelic treatment and research The Caribbean nation of Saint Vincent and the Grenadines has launched an initiative to permit and support psychedelic research and wellness. The initiative will begin as a Medicinal Wellness Feasibility Study, which is expected to last 24 to 30 months, andContinue reading
THE PSYCHEDELICS NEWSLETTER
Expert analysis and intelligence, straight to your inbox. Join industry insiders and subscribe for exclusive news, data and insights from across the psychedelics industry.
ISSUES
Issue 13
The psychedelic compound known as DMT will be used in a trial to treat depression for the first time in the United Kingdom while MDMA has been proven to help people suffering from alcohol addiction.
Issue 14
PSYCH hits 25,000 subscribers to become industry’s fastest-growing newsletter while a number of major announcements on the advancement of research into psychedelic medicines have been made.
